Toxic Material Removed Patents (Class 604/5.04)
  • Patent number: 10441699
    Abstract: A blood purification apparatus includes a blood circuit, a dialyzer capable of purifying the blood flowing through the blood circuit, a blood pump provided to an arterial blood circuit and that delivers the blood in the blood circuit, and an air-trap chamber capable of collecting air in the blood flowing through the blood circuit. A peristaltic pump (a substitution-fluid-infusion device) that is capable of infusing a substitution fluid is connected to the air-trap chamber. A substitution fluid layer is formable on a blood layer in the air-trap chamber. The air-trap chamber is provided with a blood-interface-detecting device that is capable of detecting an interface between the blood layer and the substitution fluid layer that are formed in the air-trap chamber. A lack of substitution fluid in the air-trap chamber is detectable on the basis of the interface between the blood layer and the substitution fluid layer that is detected by the blood-interface-detecting device.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 15, 2019
    Assignee: NIKKISO COMPANY LIMITED
    Inventor: Hiroaki Mochizuki
  • Patent number: 10016552
    Abstract: A device for degassing liquids, in particular liquids used in dialysis, has a degassing unit that includes an ultrasonic unit. Liquids to be degassed are treated in the degassing unit by ultrasound from the ultrasonic unit. Degassed liquids are discharged from the degassing unit through a hollow channel in the ultrasonic unit, and are available for further use.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: July 10, 2018
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND
    Inventor: Michael Koch
  • Patent number: 9925321
    Abstract: It is disclosed an apparatus for extracorporeal blood treatment (1) having a control unit (15) connected to an ultrafiltration device (20) and to a fluid preparation section (30) of fresh dialysis liquid. The control unit (15) is configured to receive measured values of the change of blood volume, the amount of ultrafiltration volume, and conductivity or to the concentration for at least one substance in the blood (BV %mes(t); UFmes(t), WLmes(t); Cbmes(t)); the control unit (15) is also configured to receive prescription values for the same parameters and to control ultrafiltration and adjust conductivity in the fresh dialysis liquid based on the difference between said measured values and said prescription values.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 27, 2018
    Assignee: Gambro Lundia AB
    Inventors: Alessandro Surace, Paolo Rovatti
  • Patent number: 9717836
    Abstract: Disclosed herein are methods, systems and devices to monitor vascular volume status utilizing at least one oximetry/photoplethysmography sensor. The methods, systems and devices provide an alternative to conventional vascular volume monitoring methods while enabling reliable, non-invasive, and automatic monitoring of vascular volume to avert patient hypotension. The methods, systems and devices may be employed in the context of both inpatient and outpatient facilities and may also be incorporated into conventional monitoring devices, techniques and equipment.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: August 1, 2017
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Richard J. Melker
  • Patent number: 9675748
    Abstract: A method and a kit for the prevention of venous stenosis associated with the use of hemodialysis AV shunts. The kit may use a bifurcated needle for providing access to the shunt or blood vessel. One of the arms is used for returning the blood to the subject after dialysis treatment, while the other arm is used for inserting a device for cleaning the vein, the device being either an autonomous crawling device, or a passive tethered device moved down the vein by the blood flow. The autonomous crawling device may be a series of sequentially inflatable chambers, the stenosis being cleared by pressure from the outer walls of the chambers when inflated and moved. The passive device may be an element having a flexible disc-like structure, whose flexible peripheral edge slides along the inner walls of the blood vessel, compressing or clearing the material attached thereto.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 13, 2017
    Assignees: Technion Research & Development Foundation Ltd., Microbot Medical Ltd.
    Inventors: Adi Shechtman, Moshe Shoham, Harel Gadot
  • Patent number: 9452149
    Abstract: Dialysis fluid compositions including 0.5 to 3 mM citrate, 1 to 5 mM total calcium, and 0 to 1.5 mM total magnesium. These dialysis fluid compositions include 0.10 to 0.2 mM more total calcium per 1 mM citrate within the dialysis fluid as compared to the calcium concentration ordinarily prescribed for a non-citrate containing dialysis fluid.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: September 27, 2016
    Assignee: Gambro Lundia AB
    Inventors: Anders Nilsson, Jan Sternby, Anders Wieslander
  • Patent number: 9381290
    Abstract: A dialysis system includes: a dialysis machine; and at least one of a blood pressure sensor and a weight sensor in wireless communication with the dialysis machine, wherein the dialysis machine is so positioned and arranged relative to the at least one blood pressure sensor or weight sensor that the dialysis machine is discoverable by the at least one blood pressure sensor or weight sensor when the at least one blood pressure sensor or weight sensor, respectively, is powered, and such that the at least one blood pressure sensor or weight sensor becomes paired automatically with the dialysis machine for secure wireless communication.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: July 5, 2016
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Alex Anping Yu, Robert W. Childers, Peter A. Hopping
  • Patent number: 9220829
    Abstract: Systems and methods utilize semipermeable nanotubes in conjunction with application of controlled electrical potentials across semipermeable nanotube walls allow selective transport of charged impurities (e.g., charged impurities, ions, etc.) from a fluid into these nanotubes. Impurities collected in these nanotubes can then be removed from the fluid, (e.g., blood) as a waste stream. A collection of semipermeable nanotubes each carrying a waste stream can be aggregated and merged into a ureter for excretion thereby providing an artificial kidney system. Sensors that detect/measure various impurities may be included in the system to feed information to a microprocessor to inform on concentrations of impurities, and thereby control electrical potentials applied to the system.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: December 29, 2015
    Inventor: Zvi Herschman
  • Patent number: 9155826
    Abstract: Disclosed herein are methods, systems and devices to monitor vascular volume status during renal replacement therapy utilizing at least one oximetry/photoplethysmography sensor. The methods, systems and devices provide an alternative to conventional vascular volume monitoring methods during renal replacement therapy while enabling reliable, non-invasive, and automatic monitoring of vascular volume to avert patient hypotension. The methods, systems and devices may be employed in the context of both inpatient and outpatient dialysis facilities and may also be incorporated into conventional hemodialysis and hemofiltration techniques and equipment.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: October 13, 2015
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Edward Allan Ross, Richard J. Melker
  • Patent number: 9005150
    Abstract: A renal failure therapy system includes a blood pump; a citrate pump; and a control unit configured to automatically control the blood pump and the citrate pump to achieve a citrate flowrate that is based on at least a blood flowrate.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: April 14, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Lee C. Ware, Arnold F. Boehnlein
  • Patent number: 8992453
    Abstract: The present invention relates generally to the field of hemodialysis, including methods and kits that can be employed to improve hemodialysis therapy. The present invention encompasses methods and kits useful for reducing vascular access complications associated with hemodialysis therapy and prolonging the period of time for which a vascular access site can be used in a patient.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: March 31, 2015
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Publication number: 20150088047
    Abstract: A method includes monitoring an indicator of fluid volume of a patient via a sensor device, and setting an initial fluid volume removal prescription for a blood fluid removal session based on the monitored indicator of fluid volume. The method may further include transmitting data regarding the indicator of fluid volume from the implantable sensor device to fluid removal device. The system includes a blood fluid removal device configured to set the initial fluid removal volume and rate prescription. In some embodiments, the fluid removal device sets or calculated the initial fluid volume removal prescription based on the data received from the implantable sensor. The indicator of fluid volume may be an indicator of tissue fluid volume or an indicator of blood fluid volume.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 26, 2015
    Applicant: MEDTRONIC, INC.
    Inventors: Martin Gerber, John Burnes, Suping Lyu, Manda R. VenKatesh, Bryant Pudil
  • Patent number: 8968231
    Abstract: An extracorporeal blood circuit including: a withdrawal conduit connectable to a coronary withdrawal catheter; a withdrawal pump connectable to the withdrawal conduit, wherein a pumping rate of the withdrawal pump determines a blood withdrawal rate from the coronary withdrawal catheter; a filter having an input connected to the withdrawal conduit and a blood output connected to an infusion conduit and a filtrate output connected to a filtrate conduit; a filtrate measurement device to determine an amount of filtrate removed from the blood in the filter; a fluid supplementation conduit providing a blood replacement fluid to at least one of the withdrawal conduit, filter and infusion conduit; a supplementation pump connectable to the fluid supplementation conduit, wherein a pumping rate of the supplementation pump determines a rate at which the blood replacement fluid flows into the blood flowing through the blood circuit, and a controller regulating the pumping rate of the supplementation pump such that the rat
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: March 3, 2015
    Assignee: Gambro UF Solutions, Inc.
    Inventors: Steven J. Bernard, John J. O'Mahony, Andrew V. Halpert, Mark Gelfand, Howard R. Levin
  • Publication number: 20150045713
    Abstract: Devices and methods for the prognosis of intradialytic parameters such as a blood pressure are described, wherein at least one learning algorithm and/or at least one neural network is/are provided. A memory device stores patient-individual intradialytic parameters, laboratory parameters, and/or machine parameters, which can be used in the prognosis of patient-specific parameter progress during a dialysis treatment.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 12, 2015
    Inventors: RICHARD ATTALAH, JANOSCH HENZE, CHRISTOF STROHHOEFER
  • Patent number: 8951221
    Abstract: The invention relates to a method and device for the treatment of glaucoma, though insertion of an implant into the lumen of the Schlemm's canal to realize proper drainage of the aqueous humor, which implant is brought into its position in the Schlemm's canal by means of a catheter having a distal and a proximate portion and provided with a number of pores through which a gaseous or fluid medium which comes from a pressure source can emerge during insertion of the catheter carrying the implant into the Schlemm's canal, and while the catheter is being inserted into the Schlemm's canal the gaseous or fluid medium is released under pressure thereby expanding the Schlemm's canal and the implant and upon releasing the implant at its determined location, the catheter can be withdrawn from the Schlemm's canal.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: February 10, 2015
    Assignee: Grieshaber Ophthalmic Research Foundation
    Inventors: Robert Christopher Stegmann, Matthias Christian Grieshaber, Hans Rudolf Grieshaber
  • Patent number: 8945038
    Abstract: A surgical technique and device wherein an indwelling tube is placed in the eye of a patient having glaucoma. The tube diverts aqueous humor from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. This decreases the intraocular pressure.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: February 3, 2015
    Assignee: Transcend Medical, Inc.
    Inventor: Michael Yablonski
  • Patent number: 8945037
    Abstract: A blood purification apparatus has a dialyzer (1), an arterial blood circuit (2) with a blood pump 4, a venous blood circuit 3, a dialysate introduction line L1, a dialysate discharge line L2, a substitution line L3, and a substitution pump 9 that supplies the dialysate flowing in the substitution line L3 to the arterial blood circuit 2. A control device (11) estimates or measures the concentration of blood in a dilution channel section A. The control device (11) controls the volume of dialysate supplied by the substitution pump 9 on the basis of the estimated or measured blood concentration.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: February 3, 2015
    Assignee: Nikkiso Company Limited
    Inventors: Shinya Hasegawa, Masahiro Toyoda
  • Patent number: 8945036
    Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: February 3, 2015
    Assignee: Henry Ford Health System
    Inventors: Balazs Szamosfalvi, Stanley Frinak, Jerry Yee
  • Publication number: 20150032043
    Abstract: A renal failure blood therapy system includes a renal failure blood therapy machine, a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels for each of a first solute and a second solute at each of the multiple times, and a device programmed to (i) estimate at least one first patient parameter using the determined concentration levels for the first solute, (ii) estimate at least one second patient parameter using the determined concentration levels for the second solute, (iii) determine a first plurality of acceptable treatments using the at least one first patient parameter, (iv) determine a second plurality of acceptable treatments using the at least one second patient parameter, and (v) merge the first plurality of acceptable treatments with the second plurality of acceptable treatments to determine a plurality of clinically acceptable treatments for both the first solute and the second solute.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 29, 2015
    Inventors: Alp Akonur, John Kenneth Leypoldt, Ying-Cheng Lo, Baris Ugur Agar
  • Patent number: 8926541
    Abstract: This invention relates to a means of clearing out a cholesterol, calcium and plaque build-up resident to a living circulatory system, in addition to dissolving various kinds of blood clots, and removing other foreign matter, all by means of charged particle migration, through the application of an electromotive source.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: January 6, 2015
    Inventor: Gary O. Sandstedt
  • Patent number: 8926543
    Abstract: The invention provides a way of producing a natural immunologically active state in a person by subjecting him to an apheresis procedure with bioincompatible biomaterials for about one hour. To safely control the immunological shock induced by this procedure, the person is put under general anesthesia for about six hours, including the apheresis time and at least an additional five hours thereafter. This immunological activation is useful for treating malignant tumors and diseases related to immunosuppression, such as AIDS. The invention also provides for the use of an apheresis column containing a blood perfusion filter with bioincompatible materials for treating malignant tumors and infectious diseases.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: January 6, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazuhide Ohta, Hiroshi Miyamoto, Junji Takaba, Ako Nosé
  • Patent number: 8926551
    Abstract: Patients suffering from acute renal failure must be diagnosed and treated quickly so that a physician can confidently prescribe either peritoneal dialysis or hemodialysis. In one way of quickly treating the patients, software is used to calculate a suitable peritoneal dialysis prescription without regard to how short or how long a dialysis cycle is used, and without regard to a total dialysate fluid volume for a therapy. For patients with suitable peritoneal membrane transport properties, the software program suggests that, at least over a short period of time, unexpectedly high ultrafiltrate volumes and high clearances may be achieved.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: January 6, 2015
    Assignees: Baxter Healthcare Inc., Baxter Healthcare S.A.
    Inventors: Ying-Cheng Lo, Alp Akonur, Yuanpang S. Ding
  • Patent number: 8915876
    Abstract: The present invention relates to a method for removing blood from an extracorporeal blood circuit and/or a functional device, each connectable or connected with a blood treatment apparatus for the purpose of blood treatment of a patient. The blood treatment apparatus of the method comprises or is connected with at least one extracorporeal blood circuit with a line having interior portions, the extracorporeal blood circuit comprising at least one arterial line section and at least one venous line section, wherein a first section of the arterial line section is configured to be connected with a second section of the venous line section, and further comprises at least one blood pump for conveying blood within the line interior portions. The method includes the step of operating the blood pump in a second conveying direction which is opposite to a first customary conveying direction. It further relates to corresponding apparatuses.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 23, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventors: Soeren Gronau, Juergen Haecker, Ralf Mueller, Manfred Weis, Stefan Kreber, Martin Thys
  • Patent number: 8911390
    Abstract: The present invention concerns a multipart fluid system for use in CRRT, wherein the multipart fluid system comprises an anticoagulation fluid and at least one fluid from the group consisting of a dialysis fluid and an infusion fluid. According to the invention the anticoagulation fluid comprises at least 8 mM citrate, and the dialysis fluid and/or infusion fluid comprises 2-8 mM citrate and 1-5 mM total calcium. The present invention further concerns a system for regional citrate anticoagulation in an extracorporeal blood circuit.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: December 16, 2014
    Assignee: Gambro Lundia AB
    Inventor: Jan Sternby
  • Patent number: 8889004
    Abstract: This disclosure generally relates to dialysis systems and related methods. In one aspect of the invention, a dialysis system includes a device configured so that a medical fluid can pass therethrough, and the device is adapted to remove one or more substances from the medical fluid as the medical fluid passes through the device. The dialysis system can also include a sodium control system adapted to alter a sodium concentration of the medical fluid.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: November 18, 2014
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Palmer David Updyke, Harold Frederick Sandford, Benjamin Joseph Lipps, Douglas Mark Zatezalo, Michael James Beiriger, James Matthew Mullner
  • Publication number: 20140336558
    Abstract: An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft system includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. If desired, a single actuator can be used to open and close both valve devices.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventor: David L. Cull
  • Patent number: 8864699
    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: October 21, 2014
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, James J. Cole
  • Patent number: 8858880
    Abstract: Treatment of carbon monoxide poisoning of a body by removal of a portion of the blood from the body, placing the portion in an exposure cell, exposing the portion in the cell to light of wave length and intensity that causes dissociation of carbon monoxide from hemoglobin, and returning the portion to the body. The intensity and wave length of the light is sufficient to dissociate a therapeutically-effective amount of carbon monoxide from the hemoglobin in the blood. The blood is circulated from and to the body through a concentric double lumen cannula. The wave lengths of the light are 540 and/or 570 nanometers. The cell exposes the blood to at least 9.5 Joules of dissociative light per milliliter of blood, and least 9.5 Watts of dissociative light per milliliter of blood per second. Oxygen is provided to, and the dissociated carbon monoxide is removed from the system.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: October 14, 2014
    Inventor: Mark S. Smyczynski
  • Patent number: 8834400
    Abstract: Artificial kidney for gradual, and at least semi-continuous, blood treatment, wherein a blood stream is fed from a body of a living human or animal being into the artificial kidney, where anticoagulation is first effected, blood cells and molecules of large and medium molecular weight, such as proteins, are then primarily separated from plasma and fed back to the blood stream, regulating a water and salt balance by diverting excess plasma water and further removing from the blood stream, plasma or plasma water accumulated and toxic substances, by removal of specific electrolytes and waste products and wherein purified or partially purified plasma and plasma water is being carried back to the blood tract of the body.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: September 16, 2014
    Assignee: Relitech B.V.
    Inventors: Franciscus Peter Houwen, Henk Van Middendorp, Jacobus Cornelis Musters
  • Patent number: 8827942
    Abstract: The present invention relates to a method for assessing a patient's sensitivity to fluid removal from the patient's vascular system or to fluid replacement or addition with regard to the patient's hydration state, the method comprising the step of determining a value reflecting the distribution of fluid between at least two distribution spaces of the body of the patient or changes thereof from measured or calculated values, and assessing whether the value fulfils at least one criterion. It also relates to a controller, an apparatus, a device, a digital storage device, a computer program product, and a computer program.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: September 9, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventors: Paul Chamney, Ulrich Moissl, Peter Wabel, Volker Nier, Sebastian Wieskotten
  • Patent number: 8827943
    Abstract: In one aspect, the invention provides a device comprising a catheter. In another aspect, the invention provides a method of removing an agent from blood.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 9, 2014
    Assignee: University of Pittsburg—Of The Commonwealth System of Higher Education
    Inventors: George Oliviu Angheloiu, John A. Kellum, Jr., William D. Anderson, Catalin Toma
  • Patent number: 8801646
    Abstract: An extracorporeal blood system includes: an extracorporeal blood machine; an arterial line extending from the extracorporeal blood machine; a venous line extending from the extracorporeal blood machine; and an access disconnection circuit for detecting a disconnection of at least one of the arterial or venous lines from a patient, the access disconnection circuit including (i) a signal generation source having first and second signal generation source electrical lines each in electrical communication with blood traveling through one of the arterial or venous lines, (ii) a conductive pathway electrically communicating blood traveling through the arterial line with blood traveling through the venous line, and (iii) a signal processing unit positioned and arranged to process a signal generated by the source to detect the disconnection of the at least one of the arterial and venous lines.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: August 12, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: James Han, Thomas P. Hartranft, Thomas D. Kelly, Angel Lasso
  • Patent number: 8795218
    Abstract: A method of removing unwanted molecules from blood includes (i) directing a flow of blood from a patient through a first hemofilter, (ii) removing a volume of fluid from the blood using the first hemofilter, (iii) combining a volume of first substitution fluid with an outflow from the first hemofilter, the volume of first substitution fluid being substantially equal to the volume of fluid removed from the blood using the first hemofilter, (iv) directing the combined first hemofilter outflow and the first substitution fluid volume from the first hemofilter through a second hemofilter, (v) combining a second substitution fluid with outflow from the second hemofilter, and (vi) returning the combined second hemofilter outflow and the second substitution fluid volume from the second hemofilter to the patient.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: August 5, 2014
    Assignee: Nikkiso Co., Ltd.
    Inventor: Jean-Michael Lannoy
  • Patent number: 8795517
    Abstract: A machine-readable medium with instructions for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: August 5, 2014
    Assignee: Nikkiso Co., Ltd.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8790288
    Abstract: An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft system includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. If desired, a single actuator can be used to open and close both valve devices.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: July 29, 2014
    Inventor: David L. Cull
  • Publication number: 20140194804
    Abstract: A patient wearable, continuously operating extracorporeal pump apparatus which accesses the patient's arterial venous pressure differential by applying external pressure to a subcutaneous graft that has been cannualized to modulate blood flow through an extracorporeal circuit and to drive the pump for delivering a medicament, such as an anticoagulant, to the site of an intravenous cannula to prevent clogging thereof and also to move a dialysate through a circuit, including a dialyzer and a dialysate rejuvenating cartridge, whereby kidney failure can be treated without recourse to prior art hemodialysis machines found in most treatment facilities. With slight modification, the present invention can be used to remove excess fluids from CHF patients, to remove toxins from the blood in those suffering from liver failure and to facilitate administration of insulin to diabetics and/or glucose to those having hypoglycemia.
    Type: Application
    Filed: January 28, 2014
    Publication date: July 10, 2014
    Inventor: Arnold J. Lande
  • Patent number: 8771215
    Abstract: A machine (1) for extracorporeal blood treatment comprises a device (2) for ultrafiltration of a liquid through a semi-permeable membrane (3) of a blood treatment device (4), a first sensor (11) for ultrafiltration rate through the membrane, a second group of sensors (13) for measuring a trans-membrane pressure, an infusion line (16) with an infusion pump (17) and a programmed controller (14) for calculating a maximum infusion rate as a function of the transmembrane pressure. The machine is suitable for kidney failure treatments, such as hemofiltration and hemodiafiltration. In a relatively short time the machine enables a large quantity of corporeal blood to be removed from the patient.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: July 8, 2014
    Assignee: Cambro Lundia AB
    Inventors: Claudio Tonelli, Bernd Wittner, Werner Beck, Helmut Hildwein, Reinhold Deppisch, Jonas Svensson, Bjorn Ericson
  • Patent number: 8764698
    Abstract: An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, a subcutaneous arteriovenous graft system is described. The system includes an arteriovenous graft having an arterial end and an opposite venous end with a first valve device positioned at the arterial end of the arteriovenous graft and a second valve device positioned at the venous end of the arteriovenous graft. The system also includes an actuator having an accumulator. The actuator is in communication with both the first valve device and the second valve device and is configured to cause each valve device to open or close simultaneously. The accumulator assists in maintaining a generally constant pressure when the actuator causes each valve device to close.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: July 1, 2014
    Assignee: CreatiVasc Medical, LLC
    Inventor: David L. Cull
  • Patent number: 8764695
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 1, 2014
    Inventor: Isaac Eliaz
  • Patent number: 8758287
    Abstract: A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: June 24, 2014
    Assignee: Marv Enterprises, LLC
    Inventor: Mitchell S. Felder
  • Patent number: 8758286
    Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: June 24, 2014
    Assignee: Exthera Medical Corporation
    Inventors: Robert S Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
  • Patent number: 8753515
    Abstract: Systems and methods are disclosed for performing hemodialysis that include fluid handling systems that provide accurate control over the type and level of hemodialysis being performed. The system includes a first pump for pumping dialysate into a dialyzer and a second pump for pumping dialysate out of the dialyzer. The system also includes a third pump that provides improved control of a level of ultrafiltration, hemodiafiltration, or both.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: June 17, 2014
    Assignee: Home Dialysis Plus, Ltd.
    Inventors: James R. Curtis, Ladislaus F. Nonn, Julie Wrazel
  • Patent number: 8721884
    Abstract: Disclosed are hemodialysis and similar dialysis systems including fluid flow circuits. Hemodialysis systems may include a blood flow path, and a dialysate flow path including balancing, mixing, and/or a directing circuits. Preparation of dialysate may be decoupled from patient dialysis. Circuits may be defined within one or more cassettes. The fluid circuit and/or the various fluid flow paths may be isolated from electrical components. A gas supply may be provided that, when activated, is able to urge dialysate through the dialyzer and blood back to the patient. Such a system may be useful during a power failure. The hemodialysis system may also include fluid handling devices, such as pumps, valves, mixers, etc., actuated using a control fluid. The control fluid may be delivered to the fluid handling devices using a detachable external pump. The fluid handling devices may have a spheroid shape with a diaphragm dividing it into two compartments.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: May 13, 2014
    Assignee: DEKA Products Limited Partnership
    Inventors: Michael J. Wilt, Jason A. Demers, Kevin L. Grant, Brian D. Tracey, James D. Dale
  • Patent number: 8721883
    Abstract: The invention relates to an apparatus for the treatment of a medical liquid comprising a liquid treatment machine and a cassette insertable therein substantially made of a rigid base body of the cassette with fitted chambers and passages and a foil covering them.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 13, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventor: Martin Lauer
  • Patent number: 8715213
    Abstract: The present invention has as an object to provide a bone metabolism improving agent that improves bone metabolism in a chronic renal failure patient receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration. An acetic acid- and/or acetate salt-free bone metabolism improving agent that contains citric acid and/or a citrate salt as electrolytes and further contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. A bone metabolism improving agent formulated into a dialysate or a substitution fluid having effects of improving bone metabolism including bone metabolism improvement in adynamic bone disease and especially in bone agenesis is also provided.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: May 6, 2014
    Assignee: Ajinomoto Co., Inc.
    Inventors: Hidehiro Yamazaki, Toshihiro Ohki, Tomio Inaba, Naomi Sakaguchi
  • Patent number: 8715215
    Abstract: A method of checking and/or monitoring the correct operation of an adding device of a medical apparatus includes detecting a characteristic signal course being generated by the adding device. The medical apparatus includes an extracorporeal circuit with which the adding device is connected such that an agent can be introduced into the extracorporeal circuit via the adding device. The pressure loss in the extracorporeal circuit is measured and evaluated for checking and/or monitoring the correct operation of the adding device. The adding device for this purpose generates an oscillating pressure course.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: May 6, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventor: Pascal Kopperschmidt
  • Patent number: 8708943
    Abstract: An apparatus for hemo(dia)filtration comprises an extracorporeal blood circuit and a supply line of a replacement fluid to the extracorporeal blood circuit. The supply line has a bifurcation which divides a main branch (24) into a pre-dilution branch (25) and a post-dilution branch (26). A pump tube tract (29) is predisposed in the supply line for coupling with a circuit pump of the replacement fluid. An expansion chamber is predisposed in the extracorporeal blood circuit and is fluidly connected to the pre-dilution branch. The invention provides a disposable fluid circuit usable for performing a hemodiafiltration treatment with pre-dilution and post-dilution which is couplable simply, rapidly, economically and reliably to a machine for monitoring the treatment.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: April 29, 2014
    Assignee: Gambro Lundia AB
    Inventors: Luca Caleffi, Marco Paraluppi, Giuseppe Franzoni
  • Patent number: 8708946
    Abstract: An extracorporeal blood machine includes a blood circuit; an access device enabling the blood circuit to be connected to a patient; first and second coupling devices for connecting to first and second tubes of the circuit; first and second electrodes held by the first and second coupling devices to contact blood flowing through the blood circuit, the electrodes enabling an electrical signal to be injected into the circuit; first and second contact members contacting the first and second electrodes, wherein at least one of the coupling devices includes a stem portion enabling at least one of the first and second contact members to contact at least one of the first and second electrodes, respectively, on an outer portion of the at least one electrode without disturbing blood flowing through the coupling device; and electronics coupled operably to the first and second contact members for applying the electrical signal.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: April 29, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: James Han, Thomas P. Hartranft, Thomas D. Kelly, Angel Lasso
  • Patent number: 8702638
    Abstract: A method and apparatus for controlling blood withdrawal and infusion flow rate with the use of a pressure controller. The pressure controller uses pressure targets based upon occlusion limits that are calculated as a function of flow. The controller has the ability to switch from controlling withdrawal pressure to controlling infusion pressure based upon the detection of an occlusion. The controller distinguishes between partial and total occlusions of the withdrawal vein providing blood access. Depending on the nature of occlusion, the controller limits or temporarily reverses blood flow and, thus, prevents withdrawal vessel collapse or reverses blood flow to quickly infuse blood into the vessel without participation from operator.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: April 22, 2014
    Assignee: Gambro UF Solutions, Inc.
    Inventors: John O'Mahony, Mark Gelfand, Edward Rychlick
  • Patent number: 8696909
    Abstract: A bioartificial kidney equivalent and a process for producing the bioartificial kidney equivalent. The hybrid bioartificial kidney comprises human proximal and distal renal tubule cells grown on particular synthetic membranes.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 15, 2014
    Assignee: Gambro Lundia AB
    Inventors: David Luttropp, Bernd Krause, Markus Neubauer, Andrea Schnell, Helmut Geiger, Juergen Bereiter-Hahn, Patrick Baer, Doris Deppisch